Atika Capital Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Atika Capital Management’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-50,000	Closed	-$2.06M	–	110
2020 Q3	$2.06M	Buy	+50,000	New	+$2.16M	0.17%	100
2016 Q4	–	Sell	-10,300	Closed	-$327K	–	55
2016 Q3	$327K	Hold	10,300	–	–	0.13%	66
2016 Q2	$334K	Hold	10,300	–	–	0.14%	60
2016 Q1	$288K	Hold	10,300	–	–	0.17%	44
2015 Q4	$367K	Buy	10,300 +300	+3%	+$10.6K	0.19%	52
2015 Q3	$331K	Sell	10,000 -7,000	-41%	-$291K	0.16%	56
2015 Q2	$711K	Sell	17,000 -4,200	-20%	-$163K	0.32%	62
2015 Q1	$691K	Buy	21,200 +18,000	+563%	+$619K	0.46%	56
2014 Q4	$102K	Hold	3,200	–	–	0.07%	67
2014 Q3	$79K	Hold	3,200	–	–	0.06%	64
2014 Q2	$72K	Hold	3,200	–	–	0.06%	62
2014 Q1	$78K	Buy	+3,200	New	+$81K	0.07%	61

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

FAM

Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

Atika Capital Management's ACAD Position: Q2 2021 in Review

Atika Capital Management sold out of Acadia Pharmaceuticals (ACAD) in Q2 2021, closing a stake of 65,000 shares — an estimated $1.68M sold.

Atika Capital Management first reported a position in ACAD in Q4 2013 and held it in 10 quarters. The position peaked at $9.1M in Q4 2020. 245 funds tracked by Wall St. Rank hold ACAD as of Q2 2021.

Atika Capital Management reported no remaining Acadia Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
Atika Capital Management sold 65,000 Acadia Pharmaceuticals shares in Q2 2021, an estimated $1.68M.
Atika Capital Management first reported a position in Acadia Pharmaceuticals in Q4 2013 and held it in 10 quarters.
Atika Capital Management's Acadia Pharmaceuticals position peaked at $9.1M in Q4 2020.
245 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2021.

Based on Atika Capital Management's 13F filing for Q2 2021, filed 12 Aug 2021.